Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,883,430 papers from all fields of science
Search
Sign In
Create Free Account
MEDI4736
Known as:
Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
, MEDI-4736
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Monoclonal Antibodies
durvalumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
J. Rotman
,
C. Mom
,
E. Jordanova
,
T. D. Gruijl
,
G. Kenter
,
G. Kenter
BMC Cancer
2018
Corpus ID: 52194688
Treatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising…
Expand
2017
2017
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
F. Karzai
,
R. Madan
,
+13 authors
Jung-Min Lee
2017
Corpus ID: 78972849
162Background: Recent data suggests 25-30% of sporadic mCRPC has defects in DNA repair pathways which may confer sensitivity to…
Expand
2017
2017
Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple…
L. Pusztai
,
A. Silber
,
+9 authors
M. DiGiovanna
2017
Corpus ID: 80216683
572Background: Pathologic complete response (pCR) rates to neoadjuvant chemotherapy in TNBC plateaued at 40% with existing…
Expand
2016
2016
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
S. Antonia
,
Sang-We Kim
,
+15 authors
N. Segal
2016
Corpus ID: 78940811
9029Background: The PD-1/PD-L1 axis is an important immune inhibitory pathway contributing to tumor cell escape from…
Expand
Highly Cited
2016
Highly Cited
2016
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve…
D. Gibbons
,
Laura Qm Chow
,
+7 authors
B. Creelan
Journal of Thoracic Oncology
2016
Corpus ID: 36414628
2015
2015
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
N. Rizvi
,
J. Chaft
,
+7 authors
S. Antonia
Journal of Immunotherapy for Cancer
2015
Corpus ID: 34121799
Meeting abstracts As single agents, durvalumab (MEDI4736), a human IgG1 anti-PD-L1 antibody, and tremelimumab, a human IgG2 anti…
Expand
2014
2014
Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.
D. Fairman
,
R. Narwal
,
+10 authors
L. Roskos
2014
Corpus ID: 78932212
2602 Background: MEDI4736 is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human programmed death…
Expand
2014
2014
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
M. Callahan
,
P. Ott
,
+6 authors
J. Wolchok
2014
Corpus ID: 78568675
TPS3120^ Background: MEDI4736 (M) is a human IgG1 monoclonal antibody that binds specifically to programmed cell death ligand 1…
Expand
Review
2014
Review
2014
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.
C. Zielinski
Translational Lung Cancer Research
2014
Corpus ID: 29756761
A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab…
Expand
Review
2007
Review
2007
Implications of B 7-H 1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication andTherapy
R. HoustonThompson
,
Haidong Dong
,
E. Kwon
2007
Corpus ID: 28489257
B7-H1encompasses a recently discovered cell surface glycoprotein within the B7 family of T-cell coregulatory molecules. B7…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE